Navigation Links
FDA Approves Wyeth's Oral Contraceptive Lybrel

FDA as expected on Tuesday approved Wyeth's oral contraceptive Lybrel, which is designed to eliminate monthly menstrual periods, the Los Angeles Times reports. Lybrel, which contains a lower dose of synthetic hormones in a daily dose than traditional oral contraceptives, is taken 365 days a year with no placebo pills. The usual regimen for oral contraceptives is 21 active pills taken consecutively, followed by seven placebo pills.

According to Wyeth, 59% of women taking Lybrel stopped bleeding after six months, but 18% of women participating in a clinical trial dropped out because of bleeding or spotting. A European trial found that the drug prevented pregnancy in all 323 women who took it, according to Wyeth.

The drug has received mixed reviews from women and health experts. In a study conducted by Wyeth, nearly two-thirds of women expressed an interest in eliminating their menstrual periods. However, Wyeth research also found that nearly 50% of the women surveyed welcomed their periods as a sign that they were not pregnant and nearly 25% said they were attached to their periods as a natural part of womanhood.

Available medical research shows that the side effects of pills that suppress menstruation are similar to those of other birth control pills. The most significant risk of the pills is cardiovascular complications in women who smoke.

Daniel Shames, deputy director of FDA's Center for Drug Evaluation and Research, said that eliminating monthly periods does not appear to carry safety issues, but he added that Wyeth will continue to study Lybrel to see if unexpected safety issues occur.

FDA said that because women taking Lybrel will not have a monthly period, they should be tested if they suspect they might be pregnant, the Washington Post reports. Gerardo Bustillo, assistant ob-gyn chief at Orange Coast Memorial Medical Center, said Lybrel might appeal to women who take oral contraceptives to prevent menstrual cramps and migraine headaches or to control endometriosis. Wyeth expects to begin sales of Lybrel in July, but the price has not been determined, according to a spokesperson for the company.


'"/>




Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... ... 20, 2017 , ... ATP Science, an Australian-based company focused ... the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding meetings ... of supplements that keep the body functioning at its peak performance by providing ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... , January 19, 2017 ... Otsuka in the Milner Therapeutics Consortium   ... in Cambridge   ... PFE ) as a partner to the ... Consortium, which enables the efficient transfer of materials between ...
Breaking Medicine Technology: